Inozyme Pharma (NASDAQ:INZY – Get Free Report)‘s stock had its “outperform” rating reissued by investment analysts at Wedbush in a research report issued on Monday, Benzinga reports. They currently have a $15.00 price objective on the stock. Wedbush’s price objective indicates a potential upside of 198.80% from the stock’s current price.
Other research analysts also recently issued research reports about the stock. Needham & Company LLC reaffirmed a “buy” rating and issued a $23.00 price objective on shares of Inozyme Pharma in a research report on Tuesday, August 6th. Stifel Nicolaus began coverage on shares of Inozyme Pharma in a research note on Thursday, September 12th. They issued a “buy” rating and a $16.00 target price for the company. Jefferies Financial Group reissued a “buy” rating and set a $17.00 target price (up previously from $16.00) on shares of Inozyme Pharma in a research report on Tuesday, August 13th. Finally, HC Wainwright reiterated a “buy” rating and set a $14.00 price objective on shares of Inozyme Pharma in a research note on Thursday, August 8th. Seven research analysts have rated the stock with a buy rating, According to MarketBeat.com, Inozyme Pharma presently has a consensus rating of “Buy” and a consensus target price of $16.14.
View Our Latest Stock Analysis on Inozyme Pharma
Inozyme Pharma Stock Performance
Inozyme Pharma (NASDAQ:INZY – Get Free Report) last announced its quarterly earnings results on Tuesday, August 6th. The company reported ($0.44) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.37) by ($0.07). As a group, equities research analysts forecast that Inozyme Pharma will post -1.68 EPS for the current fiscal year.
Hedge Funds Weigh In On Inozyme Pharma
A number of institutional investors have recently modified their holdings of INZY. Millennium Management LLC lifted its holdings in Inozyme Pharma by 154.1% in the second quarter. Millennium Management LLC now owns 1,787,947 shares of the company’s stock valued at $7,974,000 after acquiring an additional 1,084,341 shares during the period. Affinity Asset Advisors LLC boosted its holdings in Inozyme Pharma by 40.1% during the first quarter. Affinity Asset Advisors LLC now owns 2,642,519 shares of the company’s stock worth $20,242,000 after buying an additional 756,717 shares in the last quarter. Samlyn Capital LLC grew its position in Inozyme Pharma by 15.0% during the second quarter. Samlyn Capital LLC now owns 3,350,535 shares of the company’s stock valued at $14,943,000 after buying an additional 437,622 shares during the period. Dimensional Fund Advisors LP grew its position in Inozyme Pharma by 117.6% during the second quarter. Dimensional Fund Advisors LP now owns 380,064 shares of the company’s stock valued at $1,695,000 after buying an additional 205,417 shares during the period. Finally, Kennedy Capital Management LLC raised its position in shares of Inozyme Pharma by 52.2% in the first quarter. Kennedy Capital Management LLC now owns 437,657 shares of the company’s stock worth $3,352,000 after acquiring an additional 150,120 shares during the period. Hedge funds and other institutional investors own 88.30% of the company’s stock.
About Inozyme Pharma
Inozyme Pharma, Inc, a clinical-stage rare disease biopharmaceutical company, focuses on developing novel therapeutics for the treatment of vasculature, soft tissue, and skeleton diseases. The company's lead product candidate is INZ-701, a soluble, recombinant, genetically engineered, and fusion protein for the treatment of ENPP1 and ABCC6 deficiencies, as well as patients with end-stage kidney disease receiving hemodialysis.
Featured Stories
- Five stocks we like better than Inozyme Pharma
- CD Calculator: Certificate of Deposit Calculator
- Why Lennar Stock Could Be the Best Play in the Housing Market
- Which Wall Street Analysts are the Most Accurate?
- 2 Energy Stocks Fueling the AI Datacenter Boom
- 3 Grocery Stocks That Are Proving They Are Still Essential
- Will Marinus Pharmaceuticals Be the Next Big Winner in Biotech?
Receive News & Ratings for Inozyme Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Inozyme Pharma and related companies with MarketBeat.com's FREE daily email newsletter.